Table 2. Prevalence of HR-HPV detection by careHPV and INNO-LiPA genotyping Extra assay according to cytological results.
|
Burkina Faso (n=426) |
South Africa (n=503) |
|||||
|---|---|---|---|---|---|---|
| Cytology | No. | careHPV-positive (%) | INNO-LiPA-positive (%) | No. | careHPV-positive (%) | INNO-LiPA-positive (%) |
| No anomalies | 368 | 148 (40.2) | 240 (65.2) | 14 | 4 (28.6) | 6 (42.9) |
| Atypical cellsa | 16 | 9 (56.2) | 12 (75.0) | 84 | 28 (33.3) | 58 (69.0) |
| LSIL | 33 | 25 (75.8) | 28 (84.8) | 316 | 114 (36.1) | 215 (68.0) |
| HSIL+ | 9 | 9 (100) | 9 (100) | 89 | 78 (87.6) | 81 (91.0) |
| Pb | <0.0001 | 0.0016 | <0.0001 | 0.0011 | ||
Abbreviations: BF=Burkina Faso; HPV=human papillomavirus; HSIL=high-grade squamous intraepithelial lesions; LSIL=low-grade squamous intraepithelial lesions; SA=South Africa.
a
Atypical squamous cells of undetermined significance (ASC-US), n=13 (BF) and n=52 (SA); Atypical squamous cells, cannot exclude HSIL (ASC-H), n=2 (BF) and n=32 (SA); Atypical glandular cells (AGC), n=1 (BF).
b
Test for trend.